Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Concurrent Ipilimumab and Dabrafenib in Unresectable Stage III or Stage IV Melanoma

NCT02200562 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT02200562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02200562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Concurrent Ipilimumab and Dabrafenib in Unresectable Stage III or Stage IV Melanoma
Lead sponsor
University of Utah
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2014
Completion date
January 20, 2017
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii or iv melanoma